Finance

Lists
Why is ANW down 5,71%?
Dive Deeper
ANW:FRA
Immuron Ltd
0,016 €
-5,71%
(-0,0010) 1D
15 հոկ, 22:00:00 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for ANW...
Open
0,02 €
High
0,02 €
Low
0,02 €
Mkt. cap
11,53 մլն
Avg. vol.
904,00
Volume
0,00
52-wk high
0,04 €
52-wk low
0,01 €
No. of employees
8
Open
0,02 €
High
0,02 €
Low
0,02 €
Mkt. cap
11,53 մլն
Avg. vol.
904,00
Volume
0,00
52-wk high
0,04 €
52-wk low
0,01 €
No. of employees
8
News stories
From web sources and news partners
Profile
Immuron is a biotechnology company based in Melbourne, Australia. In 2008, the company changed its name to Immuron Limited, having previously operated as Anadis Limited. Immuron is focused on antigen-primed and dairy-derived health products. Its proprietary technologies allow for rapid development of polyclonal antibody and other proteins-based solutions for a range of diseases. The company specialises in nutraceutical, pharmaceutical and therapeutic technology products for conditions such as oral and GI mucositis, avian influenza, E. coli travellers' diarrhoea and Anthrax containment. In 2005, Anadis signed an agreement with Quebec's Baralex Inc. and Valeo Pharma Inc. for the distribution of Travelan, a product made by Anadis for the Canadian market. Wikipedia
About Immuron Ltd
CEO-
Employees8
Founded1994
HeadquartersBlackburn North, Վիկտորիա, Ավստրալիա
Sector-
Websiteimmuron.com.au
Previous reportsAll values in AUD
Loading Previous Earnings...
Revenue
Net income
All values in AUD
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
2,09 մլն
2,09 մլն
1,76 մլն
1,76 մլն
Cost of goods sold
765,33 հզր
765,33 հզր
603,93 հզր
603,93 հզր
Cost of revenue
765,33 հզր
765,33 հզր
603,93 հզր
603,93 հզր
Research and development expenses
589,74 հզր
589,74 հզր
376,98 հզր
376,98 հզր
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,89 մլն
1,89 մլն
2,00 մլն
2,00 մլն
Operating expense
2,31 մլն
2,31 մլն
1,96 մլն
1,96 մլն
Total operating expenses
3,08 մլն
3,08 մլն
2,56 մլն
2,56 մլն
Operating income
-986,57 հզր
-986,57 հզր
-796,24 հզր
-796,24 հզր
Other non operating income
-
-
-
-
EBT including unusual items
-959,54 հզր
-959,54 հզր
-880,46 հզր
-880,46 հզր
EBT excluding unusual items
-959,54 հզր
-959,54 հզր
-880,46 հզր
-880,46 հզր
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-167,08 հզր
-167,08 հզր
-417,86 հզր
-417,86 հզր
Net income
-959,54 հզր
-959,54 հզր
-880,46 հզր
-880,46 հզր
Net profit margin
-45,86%
-45,86%
-49,90%
-49,90%
Earnings per share
-
-
-
-
Interest and investment income
30,32 հզր
30,32 հզր
62,40 հզր
62,40 հզր
Interest expense
-3,29 հզր
-3,29 հզր
-4,06 հզր
-4,06 հզր
Net interest expenses
27,03 հզր
27,03 հզր
58,33 հզր
58,33 հզր
Depreciation and amortization charges
-
-
-
-
EBITDA
-974,15 հզր
-974,15 հզր
-783,82 հզր
-785,66 հզր
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google Apps